Outrun TX is a technology company.
Outrun TX has raised $10.0M across 1 funding round.
Outrun TX has raised $10.0M in total across 1 funding round.
Outrun TX has raised $10.0M in total across 1 funding round.
Outrun TX's investors include Brandon Capital Partners, EQT Life Sciences, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Polaris Partners, Sanofi Ventures.
Outrun Therapeutics (Outrun TX) is a preclinical biotechnology company developing small molecule inhibitors that target E3 ligases to stabilize tumor suppressor proteins, primarily for treating hard-to-treat solid tumors and other diseases.[1][2][4] Founded in 2019 as a spin-out from the University of Dundee, it serves the biotech and pharmaceutical sectors by advancing a proprietary platform that has generated a lead program in oncology, supported by $10M in seed funding raised in May 2024 from M Ventures and MP Healthcare Venture Management.[1][2][3][4] The company's scalable approach addresses protein destabilization in cancer, marking early growth momentum through platform validation and investor backing.[1][4]
Outrun Therapeutics emerged in 2019 from Prof. Satpal Virdee’s lab at the University of Dundee’s MRC Protein Phosphorylation and Ubiquitylation Unit, a hub for ubiquitin system research.[2][3][4] Key founders include Principal Scientist Mathew (DPhil in Organic Chemistry from University of Sussex, with expertise in small molecule drug discovery), Dr. Kuan-Chuan Pao (PhD from MRC-PPU, postdoc at UC Berkeley, experienced in chemical and cell biology), and the broader team led by CEO Dr. Carolyn Porter.[3] The idea stemmed from deep insights into E3 ligase biology, leading to a proprietary platform for inhibitor discovery; early traction came via rapid pipeline construction, culminating in the $10M seed round in May 2024 to advance preclinical programs.[1][2][4]
Outrun rides the wave of targeted protein modulation in biotech, shifting from degradation (e.g., PROTACs) to stabilization via E3 ligase inhibition—a nascent field unlocking undruggable targets in oncology.[2][4] Timing aligns with surging demand for precision therapies in solid tumors, fueled by advances in ubiquitin biology and AI-driven drug discovery, amid a biotech funding rebound post-2023 downturn.[1][4] Market forces like aging populations and unmet needs in hard-to-treat cancers favor its platform, while its Dundee origins bolster the UK’s life sciences ecosystem, influencing pipeline diversification beyond oncology.[2][3]
Outrun’s near-term path involves advancing its lead E3 inhibitor into IND-enabling studies, leveraging $10M to expand the pipeline across diseases.[1][4] Trends like multi-modal protein therapies and ligase-focused PROTACs will accelerate validation, potentially drawing Big Pharma partnerships. Its influence may grow by pioneering stabilization modalities, evolving from preclinical innovator to a platform-licensing leader in oncology biotech. This positions Outrun TX as a high-potential bet on next-gen small molecules transforming cancer treatment.[2][4]
Outrun TX has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $10.0M Seed | Brandon Capital Partners, EQT Life Sciences, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Polaris Partners, Sanofi Ventures |